Pfizer Inc. PFE-N said it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight-loss treatments.
The company’s shares fell more than 5 per cent in early trading on Monday as Pfizer said it would stop developing its therapy lotiglipron after patients who took the drug in clinical studies were shown to have elevated levels of liver enzymes.
Pfizer chief executive Albert Bourla has said an obesity pill could eventually be a US$10-billion-a-year product for Pfizer. The company’s shares have dropped around 29 per cent so far this year as it works to develop its strategy past the COVID-19 vaccines and therapeutics that drove revenue and earnings for the past few years. The NYSE Arca Pharmaceutical Index, which tracks drugmakers, is down around 1 per cent over the same period.
The company said it expects to finalize plans for the danuglipron late-stage program by the end of the year, and is also developing a once-daily, modified release version of that drug. Pfizer has been developing both pills in parallel, but had said all things being equal its preference would be for the once-daily lotiglipron.
The news comes days after competitor Eli Lilly released promising data for its own once-daily experimental pill, orforglipron.
Truist Securities analyst Robyn Karnauskas said Lilly is now ahead in the race for a once-a-day obesity pill.
“We believe while (twice a day) has advantages, we really need a (once daily) formulation for weight loss,” she said in a research note.
Pfizer said last month that danuglipron helped patients lose weight on par with Novo Nordisk’s Ozempic in a midstage study that tested it in patients with Type 2 diabetes.
U.S. demand for Wegovy and Ozempic, the brand names for Novo Nordisk’s once-weekly injections for treating obesity and diabetes respectively, has soared recently.
The enormous demand for treatments like Wegovy could support as many as 10 competing products with annual sales reaching up to US$100-billion within a decade, mostly in the United States, industry executives and analysts have said.
None of the patients in the lotiglipron trials reported liver-related symptoms or side effects, there was no evidence of liver failure and none required treatment, Pfizer said.
Liver enzyme elevations observed in lotiglipron trials have not been seen in patients enrolled in danuglipron trials, the company added.